中年PSA与四种激肽释放酶标记物对前列腺癌死亡的二十年风险预测
基线PSA预测前列腺癌死亡的 concordance index 为0.86;PSA≥2.0ng/ml时,四标记物面板较PSA提高预测准确性(0.80 vs 0.73)。四标记物面板评分<7.5%的60岁以上男性15年前列腺癌死亡风险仅1.7%,可监测而非活检。
要点
- 基线PSA可预测前列腺癌死亡,concordance index 0.86。
- PSA≥2.0ng/ml时,四标记物面板预测准确性优于PSA(0.80 vs 0.73)。
- 四标记物面板评分<7.5%者15年死亡风险1.7%,可监测避免活检。
核心结论
- 基于四种激肽释放酶标记物的预设统计模型可重新分类许多PSA轻度升高男性为低长期前列腺癌死亡风险。
- PSA升高但四标记物面板评分低的男性可监测而非活检。
研究设计与样本
- 测量1223例前列腺癌病例和3028名对照的四种激肽释放酶标记物。
主要发现
- 基线PSA预测前列腺癌死亡的 concordance index 为0.86。
- PSA≥2.0ng/ml男性中,四标记物面板预测准确性0.80,PSA为0.73,提高0.07(95%CI 0.04, 0.10)。
- 60岁以上PSA升高男性近半数四标记物面板评分<7.5%,15年前列腺癌死亡风险1.7%。
- 四标记物面板评分≥7.5%男性15年前列腺癌死亡风险13%。
关键数值与推荐
- 四标记物面板评分<7.5%对应15年前列腺癌死亡风险1.7%,与PSA 1.6ng/ml男性相似。
- 四标记物面板评分≥7.5%对应15年前列腺癌死亡风险13%。
临床怎么用
- PSA升高男性可检测四标记物面板(商业化为4Kscore)以评估长期前列腺癌死亡风险。
- 四标记物面板评分低者建议监测而非立即活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific antigen (PSA) screening reduces prostate cancer deaths but leads to harm from overdiagnosis and overtreatment. OBJECTIVE: To determine the long-term risk of prostate cancer mortality using kallikrein blood markers measured at baseline in a large population of healthy men to identify men with low risk for prostate cancer death. DESIGN, SETTING, PARTICIPANTS: Study based on the Malmö Diet and Cancer cohort enrolling 11 506 unscreened men aged 45-73 yr during 1991-1996, providing cryopreserved blood at enrollment and followed without PSA screening to December 31, 2014. We measured four kallikrein markers in the blood of 1223 prostate cancer cases and 3028 controls. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Prostate cancer death (n=317) by PSA and a prespecified statistical model based on the levels of four kallikrein markers. RESULTS AND LIMITATIONS: Baseline PSA predicted prostate cancer death with a concordance index of 0.86. In men with elevated PSA (≥2.0ng/ml), predictive accuracy was enhanced by the four-kallikrein panel compared with PSA (0.80 vs 0.73; improvement 0.07; 95% confidence interval 0.04, 0.10). Nearly half of men aged 60+ yr with elevated PSA had a four-kallikrein panel score of <7.5%, translating into 1.7% risk of prostate cancer death at 15 yr-a similar estimate to that of a man with a PSA of 1.6ng/ml. Men with a four-kallikrein panel score of ≥7.5% had a 13% risk of prostate cancer death at 15 yr. CONCLUSIONS: A prespecified statistical model based on four kallikrein markers (commercially available as the 4Kscore) reclassified many men with modestly elevated PSA, to have a low long-term risk of prostate cancer death. Men with elevated PSA but low scores from the four-kallikrein panel can be monitored rather than being subject to biopsy. PATIENT SUMMARY: Men with elevated prostate-specific antigen (PSA) are often referred for prostate biopsy. However, men with elevated PSA but low scores from the four-kallikrein panel can be monitored rather than being subject to biopsy.
引用
- Sjoberg DD, Vickers AJ, Assel M, et al. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. Eur Urol. 2018. PMID: 29519548. doi:10.1016/j.eururo.2018.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。